1. Home
  2. GLUE vs OCSL Comparison

GLUE vs OCSL Comparison

Compare GLUE & OCSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monte Rosa Therapeutics Inc.

GLUE

Monte Rosa Therapeutics Inc.

HOLD

Current Price

$16.03

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Oaktree Specialty Lending Corporation

OCSL

Oaktree Specialty Lending Corporation

HOLD

Current Price

$12.81

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLUE
OCSL
Founded
2019
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
GLUE
OCSL
Price
$16.03
$12.81
Analyst Decision
Buy
Hold
Analyst Count
2
3
Target Price
$19.50
$14.33
AVG Volume (30 Days)
976.6K
759.5K
Earning Date
11-06-2025
02-03-2026
Dividend Yield
N/A
12.46%
EPS Growth
N/A
N/A
EPS
0.25
0.39
Revenue
$181,538,000.00
$316,801,000.00
Revenue This Year
$81.52
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$62.71
$32.56
Revenue Growth
1112.27
N/A
52 Week Low
$3.50
$12.44
52 Week High
$19.17
$16.29

Technical Indicators

Market Signals
Indicator
GLUE
OCSL
Relative Strength Index (RSI) 52.03 30.75
Support Level $14.64 $13.53
Resistance Level $19.17 $12.99
Average True Range (ATR) 1.23 0.20
MACD -0.29 -0.10
Stochastic Oscillator 30.91 5.58

Price Performance

Historical Comparison
GLUE
OCSL

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

About OCSL Oaktree Specialty Lending Corporation

Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets.

Share on Social Networks: